Key Highlights
- Net income attributable to common shareholders was USD 77.8 million for the third quarter of 2026, against a loss of USD 1.9 million a year earlier, equal to USD 5.07 per diluted share versus a USD 0.13 loss.
- A gain of USD 81.1 million on disposal of the businesses sold to Apotex Health drove the result, while the loss from continuing operations was USD 1.1 million, or USD 0.07 per diluted share.
- Cash and cash equivalents reached USD 80.6 million at September 30, 2026, from USD 11.4 million at the end of 2025, with total Assets of about USD 114 million and Equity of about USD 73 million.
- Total Revenue was USD 2.2 million for the quarter, mostly USD 1.95 million of transition services revenue, while Research and Development expense rose to USD 0.84 million from USD 0.65 million.
An Asset Sale Gain Produces the Headline Profit
Cumberland Pharmaceuticals (NASDAQ:CPIX) announced third-quarter 2026 results on November 10, 2026. The Net Income of USD 77.8 million was not operating profit. It came mainly from an USD 81.1 million gain on disposal of discontinued operations, after the company closed a strategic transaction with Apotex Health on July 1, 2026. Its commercial brands and organization moved into Apotex's U.S. branded business, and the company said it received USD 100 million of proceeds at closing. Income from discontinued operations before the gain was a loss of USD 1.7 million, and tax on the disposal was USD 0.5 million.
Continuing Operations Remain Small and Loss-Making
After the sale, the company is a development-focused biopharmaceutical Business developing therapies for rare diseases. Continuing operations posted an operating loss of USD 1.9 million, narrower than USD 2.9 million a year earlier, helped by USD 0.8 million of interest income on the larger cash balance. Revenue consisted of USD 1.95 million of transition services, which carried USD 1.1 million of cost, and USD 0.2 million of net revenue. General and administrative expense was USD 2.2 million. For nine months, net income was USD 70.2 million, or USD 4.60 diluted, against a loss of USD 0.10 a year earlier.
Ifetroban NDA Plan and the Systemic Sclerosis Readout
The company said it will submit a New Drug Application for ifetroban in cardiomyopathy associated with Duchenne muscular dystrophy, after a pre-application FDA meeting this fall. The FDA granted a rolling review, so completed sections can be filed early. The Phase 2 FIGHT DMD trial showed a 5.4 point gain in left ventricular ejection fraction in the high-dose group versus a combined control group, with a reported p-value of 0.002. Top-line data from the Phase 2a systemic sclerosis trial reported no serious adverse event assessed as related to the drug, but the company gave no efficacy figures and will decide on further development after more analyses. Filing timing and approval are not assured.
Where Things Stand
The jump was an accounting result of selling the commercial business, not a sign that the remaining pipeline company turned profitable. Cumberland Pharmaceuticals (NASDAQ:CPIX) booked USD 77.8 million of net income, yet continuing operations lost USD 1.1 million, and revenue is largely temporary transition services. The stronger cash position of USD 80.6 million funds the ifetroban work, with next markers being the rolling NDA submission, the systemic sclerosis analyses and any later share price reaction, which the release does not describe.






Please wait processing your request...